Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

More Like This

Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)

Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

Alberto Toso, Chief Scientific Officer of Alentis Therapeutics (Photo: Alentis Therapeutics)

Alentis Appoints Alberto Toso Chief Scientific Officer

Jon Freve, Chief Financial Officer of Alentis Therapeutics (Photo: Alentis Therapeutics)

Alentis Appoints Jonathan Freve CFO

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

Dr. William Pao has joined Alentis Therapeutics' Board of Directors as an independent member. (Photo: Alentis Therapeutics)

William Pao Joins Alentis Therapeutics as Independent Board Member